Prostate-Specific Membrane Antigen-Ligand Therapy: What the Radiologist Needs to Know

Area of Science:

• Nuclear Medicine
• Oncology
• Radiopharmaceutical Therapy

Background:

• Prostate-specific membrane antigen (PSMA) targeted radioligands have transformed nuclear medicine.
• PSMA radioligand therapy (PRLT) is effective for metastatic castration-resistant prostate cancer.
• PRLT enhances the role of nuclear medicine physicians in direct patient care.

Purpose of the Study:

• To review clinical data on PRLT efficacy and toxicities.
• To outline essential personnel and practical aspects for PRLT centers.
• To provide an overview of future directions in PRLT.

Main Methods:

• Review of clinical study data on PSMA radioligand therapy.
• Discussion of efficacy, toxicities, and management implications.
• Analysis of personnel requirements and clinical examples for PRLT implementation.

Main Results:

• PRLT demonstrates life-prolonging benefits in metastatic prostate cancer.
• Understanding clinical context and management is crucial for effective PRLT delivery.
• The review provides a comprehensive guide for implementing and managing PRLT.

Conclusions:

• PSMA radioligand therapy is a significant advancement in prostate cancer treatment.
• Nuclear medicine professionals must grasp the practicalities of PRLT for optimal patient care.
• Continued evolution of PRLT necessitates ongoing education and adaptation.